Search Results

Research conducted at the Phoenix Children’s Research Institute at the University of Arizona College of Medicine — Phoenix shows normalizing cancer tumor vessels and alleviating low oxygen levels in the tumor microenvironment can improve the effectiveness of chemotherapy treatment in lung cancer, according to a paper published in EMBO Molecular Medicine.

Novartis, Biogen, Takeda and Novo Nordisk are all betting on advances in the molecular glue degraders space, collectively investing billions in hopes of treating cancer, Alzheimer’s disease, cardiometabolic disease and more.

Molecular Designs, known for its market leadership in the design and production of molecular technologies, is pleased to announce the appointment of Michael Clark as its new Chief Executive Officer.

City of Hope, one of the largest cancer research and treatment organizations in the United States, announced the appointment of Alan H. Bryce, M.D., as the chief clinical officer at City of Hope Cancer Center Phoenix and professor of molecular medicine at Translational Genomics Research Institute, part of City of Hope.

According to a study published in Nature Communications, research conducted at the Phoenix Children’s Research Institute at the University of Arizona College of Medicine — Phoenix, shows how frequent non-coding FOXF1 gene deletions that interfere with important DNA regulatory regions, called enhancers, can lead to Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV), a rare, lethal, genetic lung disease which causes respiratory failure in newborns and infants.

Research conducted at the Phoenix Children’s Research Institute at the University of Arizona College of Medicine — Phoenix reports the successful generation of a mouse lung in a rat, according to a paper published in the American Journal of Respiratory and Critical Care Medicine.